A Phase 1 Study of LNCB74 in Advanced Solid Tumors

Cannot have received: investigational agent

Has received prior investigational agents within 4 weeks prior to treatment.

Cannot have received: immunotherapy (non-antibody-based therapy)

Has received anti-cancer chemotherapy (Immunotherapy (non-antibody-based therapy), retinoid therapy, hormonal therapy within 2 weeks prior to treatment.

Cannot have received: retinoid therapy

Has received anti-cancer chemotherapy (Immunotherapy (non-antibody-based therapy), retinoid therapy, hormonal therapy within 2 weeks prior to treatment.

Cannot have received: hormonal therapy

Has received anti-cancer chemotherapy (Immunotherapy (non-antibody-based therapy), retinoid therapy, hormonal therapy within 2 weeks prior to treatment.

Cannot have received: antibody-based anti-cancer therapy

Has received antibody-based anti-cancer therapy within 4 weeks prior to treatment.

Cannot have received: targeted agents and small molecules

Has received targeted agents and small molecules within 2 weeks or 5 half-lives, whichever is longer.

Cannot have received: platinum-based chemotherapy

Exception: progressed within 4 weeks of initiating therapy (platinum-refractory disease)

Has received prior platinum-based chemotherapy and progressed within 4 weeks of initiating therapy (platinum-refractory disease)

Cannot have received: antibody-drug conjugate

Exception: ADC with MMAE payload

Has received an ADC with MMAE payload.

Cannot have received: radiation therapy

Exception: focal radiation within 2 weeks or wide-field radiotherapy within 4 weeks

Has received prior radiotherapy within 2 weeks of start of study treatment for focal radiation or within 4 weeks for wide-field radiotherapy